Diroximel fumarate (DRF)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Diroximel fumarate (DRF). Diroximel fumarate is converted in the gut to the active monomethyl fumarate. Fully referenced neurology checklist.
Mechanism of action
- Diroximel fumarate is converted in the gut to the active monomethyl fumarate
- Gastrointestinal side effects are less frequent than with Dimethyl fumarate
Indication
Locked: subscribe to see this section.
Dose
Locked: subscribe to see this section.
Side effects
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Naismith RT, Wolinsky JS, Wundes A, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler 2019; 4:1352458519881761.
- Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 Study. CNS Drugs 2020; 34:185-196.
